Searchable abstracts of presentations at key conferences in endocrinology

ea0090p390 | Endocrine-related Cancer | ECE2023

Efficacity of combination of Lenvatinib and PPRT in severe hypersecretion of VIP

Raluca Mitru Natalia , Hadoux Julien , Lamartina Livia , Pani Fabiana , Baudin Eric , Moog Sophie

Introduction: VIPomas are rare neuroendocrine tumors (NET), usually located in the pancreas that secrete vasoactive intestinal polypeptide (VIP) leading to high-volume watery diarrhea and complications such as hypokalemia, acidosis and dehydration. The management of VIPoma symptoms is often challenging when surgical resection of all the lesions is not feasible. Treatments are then based on somatostatin analogs (SSA) and may also include hepatic chemoembolization, systemic chem...

ea0049ep179 | Endocrine tumours and neoplasia | ECE2017

Serum succinate: investigation of its putative role as a new biomarker in malignant SDH-x mutated pheochromocytoma-paraganglioma patients?

Lamy Constance , Hadoux Julien , Mercier Lionel , Bailleux Dorian , Hescot Segolene , Paci Angelo , Baudin Eric , Broutin Sophie

Introduction: Malignant paraganglioma/pheochromocytoma (MPP) are very rare neuroendocrine tumors with heterogeneous prognostic and no gold-standard treatment. MPP can be associated with germline mutations at SDH-x genes which encode for the succinate dehydrogenase that catalyzes the oxidation of succinate to fumarate. SDH-x mutations lead to inactivation of the enzyme and thus accumulation of succinate.Aim: This project aims to evaluate...

ea0089t5 | Trials In Progress | NANETS2022

A Phase 2 Open-Label Study of Belzutifan (a HIF-2α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors

Jimenez Camilo , Hadoux Julien , Del Rivero Jaydira , Das Satya , Iliopoulos Othon , Sultanbaev Alexander , Artamonova Elena , Jonasch Eric , Pacak Karel , Wang Wei , Jin Fan , S. Naik Girish , Capdevila Jaume

Background: Patients with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (panNET) are in need of novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is one of the key oncogenic drivers in neuroendocrine tumors. Hypoxia signaling pathway alterations or other mechanisms that stabilize HIFs are common in some PPGLs and panNETs. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in advanced renal cell...

ea0032p544 | Endocrine tumours and neoplasia | ECE2013

Multimodal combination of interferon and loco-regional treatment for disease control in progressive metastatic pheochromocytoma/paraganglioma patients

Hadoux Julien , Deandreis Desiree , Caramella Caroline , Leboulleux Sophie , Al Ghuzlan Abir , Chougnet Cecile , Dumont Frederic , Deschamps Frederic , Schlumberger Martin , Baudin Eric

Interferon-α (IFN-α) has shown some activity in neuroendocrine tumors with disease stabilizations. Malignant pheochromocytoma and paraganglioma (MPPGLs) have a heterogeneous behavior with a slow progression rate, most of the time and a high frequency of bone metastases. Stabilizing disease and preventing skeletal-related events are two goals to achieve in the management of MPPGLs patients.This retrospective study evaluated a multimodal strategy...

ea0084ps3-15-134 | Thyroid Cancer Diagnosis & Treatment | ETA2022

Patient-reported outcomes (PROS) from patients with RET-mutant medullary thyroid cancer (MTC) and ret fusion-positive TC treated with pralsetinib in the arrow trial

Hadoux Julien , I Hu Mimi , S. Brose Marcia , Garralda Elena , Spitzweg Christine , Reguart Noemi , Do Cao Christine , D. Forster Martin , Alonso-Gordoa Teresa , Barata Teresa , Scalori Astrid , Zalutskaya Alena , Trask Peter , Subbiah Vivek

Objectives: RET alterations are targetable oncogenic drivers in TC. Patients with TC, especially those with MTC treated with the multikinase inhibitors cabozantinib and/or vandetanib (C/V), often experience significant treatment-related side effects. Pralsetinib, a selective RET tyrosine kinase inhibitor, showed efficacy in patients with RET-altered TC from the phase 1/2 ARROW trial (NCT03037385). We present the impact of pralsetinib on PROs in patients with ...

ea0090p651 | Endocrine-related Cancer | ECE2023

Impact of vascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study

Marques Puga Francisca , Al Ghuzlan Abir , Hartl Dana M. , Bani Mohamed-Amine , Moog Sophie , Pani Fabiana , Breuskin Ingrid , Guerlain Joanne , Faron Matthieu , Denadreis Desiree , Baudin Eric , Hadoux Julien , Lamartina Livia

Background: Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown.Objective: To evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs. <p class="abste...

ea0063oc5.1 | Adrenal 1 | ECE2019

Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma

Buffet Alexandre , Aim Laurene Ben , Leboulleux Sophie , Drui Delphine , Vezzosi Delphine , Libe Rossella , Ajzenberg Christiane , Bernardeschi Daniele , Cariou Bertrand , Chabolle Frederic , Chabre Olivier , Darrouzet Vincent , Delemer Brigitte , Desailloud Rachel , Goichot Bernard , Esvant Annabelle , Offredo Lucile , Herman Philippe , Laboureau Sandrine , Lefebvre Herve , Pierre Peggy , Raingeard Isabelle , Reznik Yves , Sadoul Jean-Louis , Hadoux Julien , Tabarin Antoine , Tauveron Igor , Zenaty Delphine , Favier Judith , Bertherat Jerome , Baudin Eric , Amar Laurence , Gimenez-Roqueplo Anne-Paule

Context: Paragangliomas and pheochromocytomas (PPGL) are rare neuroendocrine tumors, characterized by a strong genetic component. Indeed, up to 40% of patients carry a germline mutation in a PPGL susceptibility gene. In accordance with the international recommendations, genotyping of PPGL susceptibility genes is therefore proposed to all patients with PPGL, but it has actually never been shown whether the identification of a germline mutation in one PPGL susceptibility gene ch...